Reata Pharmaceuticals — FY2021 Earnings Presentation
25 slides from Reata Pharmaceuticals's earnings presentation, Feb 28, 2022
Slide 1: 4th Quarter and Full Year 2021 Financial Results and Update on Clinical Development Programs
4th Quarter and Full Year 2021 Financial Results and Update on Clinical Development Programs February 28, 2022 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains certain “forward-looking” statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical or present facts, are forward-looking statements, including statements reg
Slide 3: Today's Agenda
Today’s Agenda Development Update |
Slide 4: Regulatory Update on Omaveloxolone for Patients with Friedreich's Ataxia
Regulatory Update on Omaveloxolone for Patients with Friedreich’s Ataxia NDA: New Drug Application Obtained Fast Track Designation
Slide 5: Update on Bardoxolone Program
Update on Bardoxolone Program CRL: Complete Response Letter; FDA: United States Food and Drug Administration We will continue to work with the FDA to confirm our next steps on our Alport syndrome program FALCON protocol amendment submitted to FDA Type A meeting requested
Slide 6: Omaveloxolone in Friedreich's Ataxia
Omaveloxolone in Friedreich’s Ataxia
Slide 7: Friedreich's Ataxia: No Approved Therapy
Friedreich’s Ataxia: No Approved Therapy 1Rummey C, et.al. Neurol Genet. 2019; 2Rummey C, et.al. E Clinical Medicine. 2020; 3Tsou AY, et. al. J Neurol Sci. 2011; 42020 IQVIA claims data and projected diagnosed; 5Estimated by Reata and the Friedreich’s Ataxia Research Alliance (FARA) based on publicl
Slide 8: MOXIe Part 2: Summary of Efficacy
MOXIe Part 2: Summary of Efficacy One of the largest completed global interventional studies in patients with FA Enrolled a wide and representative range of patients with FA Baseline mFARS: 20 to 80 Age: 16 to 40 years old MOXIe Part 2 met its mFARS primary endpoint Improvement observed in all subse
Slide 9: MOXIe Extension: Delayed-Start Analysis Study Design
MOXIe Extension: Delayed-Start Analysis Study Design FDA suggested an exploratory, post-hoc analysis, the Delayed Start Analysis Established analysis methodology used in other neurological indications1 MOXIe Extension is ongoing to continue evaluating efficacy and safety of omaveloxolone in patients
Slide 10: Delayed-Start Analysis: Results Consistent with Persistent Effect on Disease Course
Ext. 72 (Δ2) Delayed-Start Analysis: Results Consistent with Persistent Effect on Disease Course Non-inferiority test criteria met More than 50% of the difference between groups in mFARS observed at MOXIe Part 2 Week 48 (-2.25, p=0.037) was preserved at MOXIe Extension Week 72 (-3.51, p=0.016) Point
Slide 11: Delayed-Start Analysis: Parallel Annualized Slopes
Delayed-Start Analysis: Parallel Annualized Slopes Consistent with Persistent Effect on Disease Course Longitudinal analysis was used to calculate annualized slopes in MOXIe Extension Incorporates all available data from the MOXIe Extension as of August 2021 data cut-off Placebo-to-Omav (0.45 ± 0.38
Slide 12: MOXIe Part 2: Summary of Adverse Events
MOXIe Part 2: Summary of Adverse Events AEs generally mild to moderate in severity ALT and AST increases may be related to the pharmacological activity of omaveloxolone Not associated with other indicators of liver injury SAEs SAEs reported in five omaveloxolone-treated patients (10%) and three plac
Slide 13: Omaveloxolone Pharmacology May Be Applicable to a Broad Set of Neurological Diseases
MOXIe results provide proof of concept for use of omaveloxolone in other neurological diseases Mitochondrial dysfunction and neuroinflammation are common features of FA and other neurological diseases Omaveloxolone and analogs may be applicable to the diseases listed below, and we have observed prom
Slide 14: Chronic Kidney Disease Program Updates
Chronic Kidney Disease Program Updates
Slide 15: AYAME Phase 3 Diabetic CKD Outcomes Trial in Japan
AYAME Phase 3 Diabetic CKD Outcomes Trial in Japan Kyowa Kirin, our strategic collaborator in Japan is sponsoring AYAME Randomized, double-blind, placebo-controlled, registrational trial of bardoxolone in patients with diabetic CKD in Japan Primary endpoint: time to onset of ≥ 30% decline in eGFR or
Slide 16: FALCON Phase 3 Study of Bardoxolone in Patients with ADPKD
International, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial of bardoxolone in patients with ADPKD Protocol amendment filed with the FDA: Endpoints Primary: off-treatment eGFR change from baseline at Week 108 No treatment discontinuation at Year 1 Exploratory : additional
Slide 17: RTA 901 HSP90 Modulator for Diabetic Neuropathy
RTA 901 HSP90 Modulator for Diabetic Neuropathy
Slide 18: RTA 901: Study in Patients with Diabetic Peripheral Neuropathic Pain
RTA 901: Phase 2 Study in Patients with Diabetic Peripheral Neuropathic Pain (DPNP) RTA 901 is a novel, small-molecule, orally bioavailable C-terminal Hsp90 inhibitor and Hsp70 inducer1 DPNP is a serious complication of diabetes mellitus2-4 Associated with substantial morbidity, including often debi
Slide 19: Financial & Operational Update
Financial & Operational Update
Slide 20: Significant U.S. Commercial Opportunity and Launch Readiness
Significant U.S. Commercial Opportunity and Launch Readiness 1Estimated by Reata and the Friedreich’s Ataxia Research Alliance (FARA) based on publicly available data and from Vankan P, J Neurochem 2013; 22019 IQVIA claims data and projected diagnosed; 3Eight Collaborative Clinical Research Networks
Slide 21: Key Items at Dec 31, 2021 and Financial Summary
Key Items at Dec 31, 2021 Cash and Cash Equivalent $590M Total Shares Outstanding 36.4M 31.5M class A shares outstanding 4.9M class B shares outstanding Updated Cash Guidance: Based on our operational plans, we are extending cash guidance from mid-2024 to the end of 2024 Financial Summary 1Excludes
Slide 22: Reconciliation of GAAP to Non-GAAP Financial Measures
Reconciliation of GAAP to Non-GAAP Financial Measures
Slide 23: Concluding Remarks
Concluding Remarks
Slide 24: Reata at a Glance
Reata at a Glance Initiated rolling submission of NDA for omaveloxolone in FA Plan to complete submission by the end of Q1 2022 Plan to initiate Phase 2 study of RTA 901 in DPNP in second half of 2022 Received CRL and will work with FDA to confirm next steps on Alport program FALCON protocol amendme
Slide 25: Thank you
Thank you